17-47283375-C-T

Variant summary

Our verdict is Likely pathogenic. Variant got 9 ACMG points: 9P and 0B. PM3_SupportingPP4_StrongPP3PM2_SupportingPS3_Moderate

This summary comes from the ClinGen Evidence Repository: The missense variant, NM_000212.3(ITGB3):c.187C>T (p.Arg63Cys), has been reported in one compound heterozygous proband (PMID:25728920) with Pathogenic variant NM_000212.2:c.505C>T Arg169Ter (PM3_supporting). The patient (GT7 in PMID:25728920/Case 2 in PMID:35286390) with this variant displayed mucocutaneous bleeding and impaired aggregation with all agonists except ristocetin, which is highly specific for Glanzmann thrombasthenia. Additionally, αIIbβ3 surface expression was reduced to 15% (<25%), as measured by flow cytometry (PP4_strong). It occurs at an extremely low frequency, with an overall allele frequency in gnomAD of 0.00002476 (MAF of 0.00005012 in the East Asian population; PM2_supporting). It is predicted damaging by in-silico tools (REVEL score of 0.98; PP3). In transiently transfected COS‐7 cells expressing Arg63Cys mutant integrin FACS analysis showed 85% reduction of αIIbβ3Cys63 expression (PS3_moderate). In summary, this variant meets the criteria to be classified as Likely Pathogenic for autosomal recessive Glanzmann Thrombasthenia based on the ACMG/AMP criteria applied, as specified by the ClinGen PD VCEP: PP4_strong, PM2_supporting, PM3_supporting, PP3, PS3_moderate (VCEP specifications version 2). LINK:https://erepo.genome.network/evrepo/ui/classification/CA8622892/MONDO:0010119/011

Frequency

Genomes: 𝑓 0.000020 ( 0 hom., cov: 32)
Exomes 𝑓: 0.000029 ( 0 hom. )

Consequence

ITGB3
ENST00000559488.7 missense

Scores

15
2
1

Clinical Significance

Likely pathogenic reviewed by expert panel P:1U:2

Conservation

PhyloP100: 7.71
Variant links:
Genes affected
ITGB3 (HGNC:6156): (integrin subunit beta 3) The ITGB3 protein product is the integrin beta chain beta 3. Integrins are integral cell-surface proteins composed of an alpha chain and a beta chain. A given chain may combine with multiple partners resulting in different integrins. Integrin beta 3 is found along with the alpha IIb chain in platelets. Integrins are known to participate in cell adhesion as well as cell-surface mediated signalling. [provided by RefSeq, Jul 2008]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Likely_pathogenic. Variant got 9 ACMG points.

PS3
For more information check the summary or visit ClinGen Evidence Repository.
PM2
For more information check the summary or visit ClinGen Evidence Repository.
PM3
For more information check the summary or visit ClinGen Evidence Repository.
PP3
For more information check the summary or visit ClinGen Evidence Repository.
PP4
For more information check the summary or visit ClinGen Evidence Repository.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect #exon/exons MANE Protein UniProt
ITGB3NM_000212.3 linkuse as main transcriptc.187C>T p.Arg63Cys missense_variant 3/15 ENST00000559488.7 NP_000203.2

Ensembl

Gene Transcript HGVSc HGVSp Effect #exon/exons TSL MANE Protein Appris UniProt
ITGB3ENST00000559488.7 linkuse as main transcriptc.187C>T p.Arg63Cys missense_variant 3/151 NM_000212.3 ENSP00000452786 P1P05106-1
ITGB3ENST00000571680.1 linkuse as main transcriptc.187C>T p.Arg63Cys missense_variant 3/91 ENSP00000461626
ITGB3ENST00000696963.1 linkuse as main transcriptc.187C>T p.Arg63Cys missense_variant 3/14 ENSP00000513002 P05106-2

Frequencies

GnomAD3 genomes
AF:
0.0000197
AC:
3
AN:
152230
Hom.:
0
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.00
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.0000441
Gnomad OTH
AF:
0.00
GnomAD3 exomes
AF:
0.0000199
AC:
5
AN:
251276
Hom.:
0
AF XY:
0.0000221
AC XY:
3
AN XY:
135814
show subpopulations
Gnomad AFR exome
AF:
0.00
Gnomad AMR exome
AF:
0.00
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.0000544
Gnomad SAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.0000352
Gnomad OTH exome
AF:
0.00
GnomAD4 exome
AF:
0.0000294
AC:
43
AN:
1461882
Hom.:
0
Cov.:
33
AF XY:
0.0000330
AC XY:
24
AN XY:
727242
show subpopulations
Gnomad4 AFR exome
AF:
0.0000597
Gnomad4 AMR exome
AF:
0.00
Gnomad4 ASJ exome
AF:
0.00
Gnomad4 EAS exome
AF:
0.0000252
Gnomad4 SAS exome
AF:
0.00
Gnomad4 FIN exome
AF:
0.00
Gnomad4 NFE exome
AF:
0.0000333
Gnomad4 OTH exome
AF:
0.0000497
GnomAD4 genome
AF:
0.0000197
AC:
3
AN:
152230
Hom.:
0
Cov.:
32
AF XY:
0.0000269
AC XY:
2
AN XY:
74376
show subpopulations
Gnomad4 AFR
AF:
0.00
Gnomad4 AMR
AF:
0.00
Gnomad4 ASJ
AF:
0.00
Gnomad4 EAS
AF:
0.00
Gnomad4 SAS
AF:
0.00
Gnomad4 FIN
AF:
0.00
Gnomad4 NFE
AF:
0.0000441
Gnomad4 OTH
AF:
0.00
Alfa
AF:
0.0000712
Hom.:
0
Bravo
AF:
0.0000302
ExAC
AF:
0.0000330
AC:
4

ClinVar

Significance: Likely pathogenic
Submissions summary: Pathogenic:1Uncertain:2
Revision: reviewed by expert panel
LINK: link

Submissions by phenotype

Glanzmann thrombasthenia Pathogenic:1Uncertain:1
Likely pathogenic, reviewed by expert panelcurationClinGen Platelet Disorders Variant Curation Expert Panel, ClinGenAug 15, 2023The missense variant, NM_000212.3(ITGB3):c.187C>T (p.Arg63Cys), has been reported in one compound heterozygous proband (PMID: 25728920) with Pathogenic variant NM_000212.2:c.505C>T Arg169Ter (PM3_supporting). The patient (GT7 in PMID: 25728920/Case 2 in PMID: 35286390) with this variant displayed mucocutaneous bleeding and impaired aggregation with all agonists except ristocetin, which is highly specific for Glanzmann thrombasthenia. Additionally, αIIbβ3 surface expression was reduced to 15% (<25%), as measured by flow cytometry (PP4_strong). It occurs at an extremely low frequency, with an overall allele frequency in gnomAD of 0.00002476 (MAF of 0.00005012 in the East Asian population; PM2_supporting). It is predicted damaging by in-silico tools (REVEL score of 0.98; PP3). In transiently transfected COS‐7 cells expressing Arg63Cys mutant integrin FACS analysis showed 85% reduction of αIIbβ3Cys63 expression (PS3_moderate). In summary, this variant meets the criteria to be classified as Likely Pathogenic for autosomal recessive Glanzmann Thrombasthenia based on the ACMG/AMP criteria applied, as specified by the ClinGen PD VCEP: PP4_strong, PM2_supporting, PM3_supporting, PP3, PS3_moderate (VCEP specifications version 2). -
Uncertain significance, criteria provided, single submitterclinical testingIllumina Laboratory Services, IlluminaApr 27, 2017The ITGB3 c.187C>T (p.Arg63Cys) variant has been reported in one study and was found in a compound heterozygous state with a nonsense variant in one patient with Glanzmann thrombasthenia, type II (Nurden et al. 2015). Control data are unavailable for this variant, which is reported at a frequency of 0.00006 in the European (non-Finnish) population of the Exome Aggregation Consortium. When the p.Arg63Cys-containing integrin was transiently expressed in COS-7 cells, αIIbβ3 protein expression was reduced by 85% compared to wild type. Immunoblotting of lysed cells from the patient also showed that pro-αIIb and mature αIIb expression was reduced, indicating that αIIbβ3 complex maturation was slowed or impaired. Based on the evidence, the p.Arg63Cys variant is classified as a variant of unknown significance but suspicious for pathogenicity for thrombasthenia of Glanzmann and Naegeli. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population. -
not specified Uncertain:1
Uncertain significance, criteria provided, single submitterclinical testingWomen's Health and Genetics/Laboratory Corporation of America, LabCorpOct 08, 2024Variant summary: ITGB3 c.187C>T (p.Arg63Cys) results in a non-conservative amino acid change located in the PSI domain (IPR016201) of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 2e-05 in 251276 control chromosomes. c.187C>T has been reported in the literature in the compound heterozygous state in at least one individual affected with Glanzmann Thrombasthenia 2 (Nurden_2015). These data do not allow any conclusion about variant significance. At least one publication reports experimental evidence evaluating an impact on protein function. The most pronounced variant effect results in 15% of normal activity (Nurden_2015). The following publication have been ascertained in the context of this evaluation (PMID: 25728920). ClinVar contains an entry for this variant (Variation ID: 631774). Based on the evidence outlined above, the variant was classified as VUS-possibly pathogenic. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
0.91
BayesDel_addAF
Pathogenic
0.44
D
BayesDel_noAF
Pathogenic
0.56
CADD
Pathogenic
31
DANN
Pathogenic
1.0
DEOGEN2
Pathogenic
0.97
D;.
Eigen
Pathogenic
1.0
Eigen_PC
Pathogenic
0.91
FATHMM_MKL
Pathogenic
1.0
D
LIST_S2
Uncertain
0.95
D;D
M_CAP
Pathogenic
0.62
D
MetaRNN
Pathogenic
0.99
D;D
MetaSVM
Pathogenic
1.1
D
MutationAssessor
Pathogenic
3.9
H;.
MutationTaster
Benign
1.0
D;D;D;D
PrimateAI
Uncertain
0.54
T
PROVEAN
Pathogenic
-6.8
D;.
Sift
Pathogenic
0.0
D;.
Sift4G
Pathogenic
0.0
D;D
Polyphen
1.0
D;.
Vest4
0.95
MutPred
0.91
Gain of catalytic residue at P62 (P = 0.0074);Gain of catalytic residue at P62 (P = 0.0074);
MVP
0.99
MPC
1.5
ClinPred
1.0
D
GERP RS
5.9
Varity_R
0.79
gMVP
0.99

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs199866795; hg19: chr17-45360741; COSMIC: COSV71383286; COSMIC: COSV71383286; API